CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 10:30 a.m. EDT.
The live webcast of the presentation will be accessible through the company’s investor relations site, with a replay available afterward.
Madrigal is focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH). Its lead drug, Rezdiffra, is the first FDA-approved therapy for MASH with moderate to advanced fibrosis and is currently in a Phase 3 trial for treating compensated MASH cirrhosis.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.